A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF
Research payments
$9,785,016
Through program year 2023, $9,785,016 in research payments was reported against A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF, across 406 payments, paid by Merck Sharp & Dohme Corporation.
- Paid by
- Merck Sharp & Dohme Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $370,926 | 23 |
| 2021 | Research | $7,226,436 | 82 |
| 2020 | Research | $2,163,655 | 293 |
| 2019 | Research | $24,000 | 8 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Anita Scribner Longview, TX Named on 40 payments
- Anthony Scarsella Beverly Hills, CA Named on 28 payments
- Robin Dretler Decatur, GA Named on 26 payments
- Javier Morales San Juan, PR Named on 24 payments
- Ronald Nahass Hillsborough, NJ Named on 18 payments
- Anthony Mills West Hollywood, CA Named on 17 payments
- Robert Grossberg Bronx, NY Named on 15 payments
- Federico Hinestrosa Altamonte Springs, FL Named on 14 payments
- Debbie Hagins Savannah, GA Named on 14 payments
- Harold Katner Macon, GA Named on 13 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.